The Honey Integrity Act directs the Secretary of Health and Human Services (through FDA) to adopt a standard of identity for honey within one year and to stand up a Honey Integrity Program to detect economically motivated adulteration (EMA) in honey entering interstate commerce. The program requires qualifying commercial honey packers to run specified forensic and chemical tests, certify compliance, report results to FDA, and to notify authorities within 24 hours if EMA is detected.
The Secretary receives authority to investigate, confirm, destroy adulterated product, publish a list of packers, and share data with federal, state, and industry stakeholders.
This bill matters for packers, importers, testing laboratories, and enforcement agencies because it shifts the front-line testing obligation onto packers who pay National Honey Board assessments, creates new certification and reporting duties, and funds enforcement through packer fees (subject to appropriations). The combination of prescribed testing methods, mandatory rapid reporting, and interagency resource provisions aims to change how adulteration is detected and handled — with implications for supply-chain costs, lab capacity, and international producers whose product is marketed in the U.S.
At a Glance
What It Does
The bill requires FDA to set a honey standard of identity and creates the Honey Integrity Program, which compels qualifying commercial honey packers to perform specified DNA and chemical testing, certify results, report findings to FDA, and refuse receipt of identified adulterated lots. It also authorizes FDA to investigate, confirm, and destroy adulterated honey and to publish a list of qualifying packers.
Who It Affects
Directly affects qualifying commercial honey packers (defined by payment to the National Honey Board), testing laboratories, U.S. Customs and Border Protection (CBP), USDA, and federal/state enforcement agencies; importers and foreign producers will feel secondary effects through market access and acceptance testing. Accredited analytical providers and law enforcement forensic labs will see new demand for specified testing protocols.
Why It Matters
The measure translates concerns about economically motivated adulteration into enforceable obligations and mandatory testing protocols tied to federal enforcement. By putting testing and reporting duties on packers and enabling interagency laboratory use, the bill reallocates compliance responsibility and creates an information-sharing regime that can alter market signals, enforcement priorities, and trade friction risks.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill starts by directing FDA to adopt a standard of identity for honey within one year using United States Pharmacopeia procedures under the Food, Drug, and Cosmetic Act. That standard, once established, will serve as the legal benchmark for labeling and misbranding enforcement under existing FD&C Act authorities.
Most of the substantive rules live in the Honey Integrity Program. Beginning 180 days after enactment, FDA must require each “qualifying commercial honey packer” — essentially packers who pay National Honey Board assessments unless specifically excluded by FDA — to test honey destined for the U.S. market using a combined protocol of forensic DNA (nuclear and mitochondrial), nuclear magnetic resonance, high-resolution mass spectrometry, and any other validated methods FDA deems part of best practice.
FDA must also set minimum sample volumes consistent with law-enforcement protocols developed with CBP and other agencies.Packers must certify compliance, report test results to FDA in the format and timing FDA prescribes, and, if a packer identifies economically motivated adulteration (EMA), notify FDA and relevant law enforcement officials within 24 hours and refuse receipt of the suspect lot. Upon receipt of an EMA alert, FDA is tasked with confirming results through federal laboratories, then investigating and, where confirmed, destroying adulterated honey.
FDA must maintain and share data with CBP, USDA, state and local enforcement, and stakeholders such as domestic producer associations.Operationally, FDA must publish and maintain a list of qualifying packers and may exclude certain packers by criteria it develops. The bill authorizes FDA to collect fees from qualifying packers to support the program, but those fees are available to be spent only to the extent appropriated.
Where FDA lacks sufficient lab resources, CBP and USDA are directed to make their laboratory capacity available to FDA.
The Five Things You Need to Know
The Secretary must adopt a standard of identity for honey within 1 year using USP procedures under section 401 of the FD&C Act.
Testing requirements kick in 180 days after enactment and apply to ‘‘qualifying commercial honey packers’’ — those who pay assessments to the National Honey Board unless excluded by FDA.
Required testing methods include a combined protocol of nuclear and mitochondrial DNA assays, nuclear magnetic resonance (NMR), high-resolution mass spectrometry (HRMS), and other forensic techniques, plus a minimum test volume set by law-enforcement protocols.
Packers that identify economically motivated adulteration must notify FDA and required law enforcement officials within 24 hours, refuse receipt of the affected honey, and report test results to FDA in the format and timing FDA specifies.
FDA is authorized to investigate and confirm EMA using federal labs, destroy confirmed adulterated honey, publish and update a list of qualifying packers, and share EMA data with CBP, USDA, state/local agencies, and producer associations.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Standard of identity for honey
This section orders FDA to establish a legally enforceable standard of identity for honey within one year using United States Pharmacopeia procedures under the FD&C Act. Practically, that standard will be the touchstone for misbranding and identity-based enforcement; manufacturers and packers will need to align product specifications and labels to the new standard once adopted.
Congressional report on enforcement actions
FDA must deliver a report to Congress within two years cataloging enforcement actions under sections 402 and 403 of the FD&C Act related to adulterated and misbranded honey. That creates a mandated data point on enforcement activity and helps Congress and stakeholders gauge how the law’s new standards and programs affect regulatory outcomes.
Establishment of the Honey Integrity Program
This subsection authorizes the program and sets its purpose: detecting economically motivated adulteration (EMA) and improving honey integrity in interstate commerce. The language gives FDA broad programmatic authority to design testing and reporting frameworks and to coordinate across agencies — effectively creating a standing surveillance and response mechanism tied to honey supply chains.
Testing, certification, reporting, and EMA response
This is the operational core: starting 180 days after enactment, qualifying packers must perform testing using a combined suite of DNA and chemical forensic methods, certify compliance to FDA, report results, and immediately report and refuse suspect lots. FDA must define EMA, specify reporting formats and timing, set minimum sample volumes through law-enforcement-aligned protocols, and confirm any EMA through federal lab findings before ordering destruction. These mechanics shift frontline detection to private packers while reserving confirmatory and remedial authority to federal agencies.
Packer list and exclusions
FDA must publish and update a registry of qualifying commercial honey packers and may create exclusion criteria. The public list is a market-facing tool that enables downstream buyers and enforcement actors to know which packers fall under the program; exclusion authority gives FDA discretion to narrow scope where appropriate but creates administrative choices that need transparent criteria.
Interagency cooperation, funding, and definitions
FDA must consult with CBP, USDA, and other agencies when setting testing requirements and may use CBP and USDA laboratory resources if its own are insufficient. The bill establishes a fee on qualifying packers to fund the program but makes fee availability contingent on appropriations. Definitions anchor the program: EMA is tied to the FD&C Act’s adulteration standard, and qualifying packers are those paying National Honey Board assessments unless excluded — a linkage that connects this regulatory scheme to an existing commodity-promotion structure.
This bill is one of many.
Codify tracks hundreds of bills on Agriculture across all five countries.
Explore Agriculture in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Domestic honey producers and packers that already test: strengthened enforcement and public sharing of EMA data will raise barriers to adulterated imports and can help restore price and market confidence for compliant domestic product.
- Consumers and retailers: clearer identity standards and a mandatory testing/reporting regime aim to reduce fraudulent or adulterated product on shelves, which supports label accuracy and consumer trust.
- Federal and state enforcement agencies: mandated reporting, a published packer list, and interagency lab access provide more timely intelligence and standardized protocols for investigating and removing adulterated honey from commerce.
- Accredited analytical and forensic laboratories: demand for high-resolution mass spectrometry, NMR, and validated DNA forensics will grow as packers procure testing services consistent with FDA’s combined protocol.
Who Bears the Cost
- Qualifying commercial honey packers: required testing, certifications, rapid reporting obligations, potential lot forfeiture or destruction, and fees will raise operating costs and administrative burden — especially for packers handling multiple supply origins.
- Importers and foreign honey producers: increased pre-market testing expectations and the risk of quick removal or destruction of identified adulterated lots create market access uncertainty and may require new export testing regimes or certifications.
- FDA, CBP, and USDA: until fees are appropriated, agencies may need to reallocate laboratory and enforcement resources to meet confirmation and investigatory duties; the bill relies on interagency cooperation in the near term, which can strain capacity.
- Small packers near the threshold of ‘‘qualifying’’ status: if exclusion criteria are not clear, some small operations could face sudden compliance costs or market exclusion depending on FDA discretion.
Key Issues
The Core Tension
The central dilemma is protecting the honey market from fraud through mandatory, science-based surveillance versus imposing significant compliance costs and rapid enforcement consequences on packers and supply chains; the law advances detection and removal of adulterated product but depends on contested technical definitions, laboratory capacity, and appropriations that can shift burdens unevenly across domestic and international stakeholders.
The bill prescribes a testing-heavy compliance regime but leaves several operationally critical elements for FDA to define: the concrete definition of ‘‘economically motivated adulteration,’’ the specific combined testing protocol and validation standards, and the minimum sample volumes tied to law-enforcement protocols. Those definitions will determine how often packers must test, which labs can perform the work, and the false-positive/false-negative profile of the surveillance system.
Without clear validation and accreditation requirements, packers and labs may face disputes over test reliability and chain-of-custody standards.
Funding and resourcing are another tension point. The bill allows FDA to collect fees from qualifying packers but conditions availability of those funds on subsequent appropriations.
That creates a mismatch: packers bear upfront testing and reporting costs while FDA’s ability to hire staff, expand federal lab capacity, or contract services depends on appropriations and interagency goodwill to share CBP/USDA labs. The 24-hour reporting trigger for identified EMA speeds enforcement but leaves open procedural protections, notice, and remediation steps before wholesale destruction or market exclusion — an area where trade partners and small businesses could raise legal and diplomatic objections.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.